AR082241A1 - COMPUESTOS PARA REDUCIR LA PRODUCCION DE AMILOIDE b - Google Patents
COMPUESTOS PARA REDUCIR LA PRODUCCION DE AMILOIDE bInfo
- Publication number
- AR082241A1 AR082241A1 ARP110102569A ARP110102569A AR082241A1 AR 082241 A1 AR082241 A1 AR 082241A1 AR P110102569 A ARP110102569 A AR P110102569A AR P110102569 A ARP110102569 A AR P110102569A AR 082241 A1 AR082241 A1 AR 082241A1
- Authority
- AR
- Argentina
- Prior art keywords
- production
- alkyl
- nitrogen
- compounds
- nch
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 229910052739 hydrogen Chemical group 0.000 abstract 1
- 239000001257 hydrogen Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000002560 nitrile group Chemical group 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos modulan la producción del péptido amiloide b (AP b) y son útiles para el tratamiento de la enfermedad de Alzheimer y otras afecciones afectadas por la producción del péptido amiloide b (AP b).Reivindicación 1: Un compuesto caracterizado por la fórmula (1) que incluye sales de éste farmacéuticamente aceptables, en donde R1 es un grupo nitrilo, o es un anillo heteroaromático de 5 ó 6 miembros que contiene de 1 a 3 heteroátomos seleccionados, independientemente, de nitrógeno, oxígeno y azufre, en donde el anillo heteroaromático se sustituye, opcionalmente, con 1 ó 2 grupos seleccionados de halo, haloalquilo C1-6, hidroxilo, amino, alcoxi C1-6 y alquilo C1-6; A se selecciona de O y CH2, o es un enlace; B se selecciona de -(CH2)n-, -CH=CH-(cis), -CH=CH-(trans) y -(CH2)nCH(R3)-; D se selecciona de O, NR3, -CH(OH)-, -CH(OR3)- y -CH(N[R3]2)-, o es un enlace; E se selecciona de -(CH2)n-, -CH=CH-(cis), -CH=CH-(trans) y -(CH2)nCH(R3)-; F se selecciona de O y NR3, o es un enlace; G se selecciona de -CH2-, -CH2-CH2-, NR3 y -N(R3)-CH2-; S, T y U se seleccionan, independientemente, de carbono y nitrógeno, siempre que no más de uno de S, T y U sea nitrógeno; R2 es, opcionalmente, 1, 2 ó 3 de los siguientes halógeno, alcoxi C1-4, OCF3, alquilo C1-4, CN; R3 es, independientemente, alquilo C1-4 o hidrógeno; y n es 0 - 3.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36442510P | 2010-07-15 | 2010-07-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR082241A1 true AR082241A1 (es) | 2012-11-21 |
Family
ID=44511486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110102569A AR082241A1 (es) | 2010-07-15 | 2011-07-15 | COMPUESTOS PARA REDUCIR LA PRODUCCION DE AMILOIDE b |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8637523B2 (es) |
| EP (1) | EP2593461B1 (es) |
| JP (1) | JP5755739B2 (es) |
| KR (1) | KR20130041944A (es) |
| CN (1) | CN102971325B (es) |
| AR (1) | AR082241A1 (es) |
| AU (1) | AU2011279412B2 (es) |
| BR (1) | BR112013000920A2 (es) |
| CA (1) | CA2805294A1 (es) |
| CO (1) | CO6670589A2 (es) |
| EA (1) | EA021527B1 (es) |
| IL (1) | IL224202A (es) |
| MX (1) | MX2013000514A (es) |
| NZ (1) | NZ606950A (es) |
| SG (1) | SG186392A1 (es) |
| TW (1) | TW201206946A (es) |
| WO (1) | WO2012009309A1 (es) |
| ZA (1) | ZA201301178B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0696663B2 (ja) | 1986-08-04 | 1994-11-30 | 東レ株式会社 | 樹脂組成物 |
| US8754114B2 (en) | 2010-12-22 | 2014-06-17 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3 |
| CN107652289B (zh) | 2012-06-13 | 2020-07-21 | 因塞特控股公司 | 作为fgfr抑制剂的取代的三环化合物 |
| US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
| US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
| KR101473081B1 (ko) | 2013-01-25 | 2014-12-16 | 영남대학교 산학협력단 | 고리형 2-다이아조-1,3-다이카보닐 화합물을 출발물질로 하는 고리형 베타-엔아미노아마이드 유도체 및 우라실 유도체의 합성방법 |
| KR102269032B1 (ko) | 2013-04-19 | 2021-06-24 | 인사이트 홀딩스 코포레이션 | Fgfr 저해제로서 이환식 헤테로사이클 |
| US9861635B2 (en) * | 2013-05-06 | 2018-01-09 | Merck Patent Gmbh | Macrocycles as kinase inhibitors |
| NO3004079T3 (es) | 2013-06-04 | 2018-06-16 | ||
| WO2014195321A1 (en) | 2013-06-04 | 2014-12-11 | Acturum Life Science AB | Triazole compounds and their use as gamma secretase modulators |
| JP6396438B2 (ja) | 2013-06-04 | 2018-09-26 | アクチュラム・ライフ・サイエンス・アクチエボラーグ | トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 |
| WO2015153709A1 (en) * | 2014-04-02 | 2015-10-08 | Bristol-Myers Squibb Company | Difluoromethoxy compound with low bioactivation potential for the reduction of beta-amyloid production |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
| MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
| WO2016134294A1 (en) | 2015-02-20 | 2016-08-25 | Incyte Corporation | Bicyclic heterocycles as fgfr4 inhibitors |
| US10717749B2 (en) | 2015-09-29 | 2020-07-21 | Bayer Pharma Aktiengesellschaft | Macrocyclic sulfondiimine compounds |
| CA3001085A1 (en) | 2015-10-08 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Novel modified macrocyclic compounds |
| WO2017060322A2 (en) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Ptefb-inhibitor-adc |
| CA3057892A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| WO2018177889A1 (en) | 2017-03-28 | 2018-10-04 | Bayer Aktiengesellschaft | Novel ptefb inhibiting macrocyclic compounds |
| AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
| SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
| BR112020022373A2 (pt) | 2018-05-04 | 2021-02-02 | Incyte Corporation | sais de um inibidor de fgfr |
| WO2020151682A1 (zh) * | 2019-01-23 | 2020-07-30 | 成都先导药物开发股份有限公司 | 一种大环类免疫调节剂 |
| SG11202107389SA (en) * | 2019-01-29 | 2021-08-30 | Shandong Xuanzhu Pharma Co Ltd | Hexone glucokinase inhibitor and use thereof |
| WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
| WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021067374A1 (en) | 2019-10-01 | 2021-04-08 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076602A1 (en) | 2019-10-14 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| JP7720840B2 (ja) | 2019-12-04 | 2025-08-08 | インサイト・コーポレイション | Ｆｇｆｒ阻害剤としての三環式複素環 |
| CN115151539A (zh) | 2019-12-04 | 2022-10-04 | 因赛特公司 | Fgfr抑制剂的衍生物 |
| WO2021146424A1 (en) | 2020-01-15 | 2021-07-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
| US12065494B2 (en) | 2021-04-12 | 2024-08-20 | Incyte Corporation | Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent |
| AR126102A1 (es) | 2021-06-09 | 2023-09-13 | Incyte Corp | Heterociclos tricíclicos como inhibidores de fgfr |
| CA3220155A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1951730E (pt) * | 2005-11-16 | 2010-08-27 | S Bio Pte Ltd | Derivados de pirimidina ligados a heteroalquilo |
| US7932261B2 (en) * | 2006-02-06 | 2011-04-26 | Janssen Pharmaceutica Nv | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) |
| ITMI20061513A1 (it) | 2006-07-31 | 2008-02-01 | Poli Costruzione Materiali Trazione Spa | Unita' frenante compatta a disco per veicoli su rotaia |
| WO2009073777A1 (en) * | 2007-12-06 | 2009-06-11 | Schering Corporation | Gamma secretase modulators |
| MX2010006378A (es) * | 2007-12-11 | 2010-09-07 | Schering Corp | Moduladores de gamma secretasa. |
| US7923450B2 (en) * | 2008-01-11 | 2011-04-12 | Hoffmann-La Roche Inc. | Modulators for amyloid beta |
-
2011
- 2011-07-11 TW TW100124501A patent/TW201206946A/zh unknown
- 2011-07-12 KR KR1020137003728A patent/KR20130041944A/ko not_active Withdrawn
- 2011-07-12 JP JP2013519760A patent/JP5755739B2/ja not_active Expired - Fee Related
- 2011-07-12 EA EA201270824A patent/EA021527B1/ru not_active IP Right Cessation
- 2011-07-12 CA CA2805294A patent/CA2805294A1/en not_active Abandoned
- 2011-07-12 MX MX2013000514A patent/MX2013000514A/es active IP Right Grant
- 2011-07-12 NZ NZ606950A patent/NZ606950A/en not_active IP Right Cessation
- 2011-07-12 CN CN201180034655.5A patent/CN102971325B/zh not_active Expired - Fee Related
- 2011-07-12 AU AU2011279412A patent/AU2011279412B2/en not_active Ceased
- 2011-07-12 SG SG2012093274A patent/SG186392A1/en unknown
- 2011-07-12 US US13/180,623 patent/US8637523B2/en active Active
- 2011-07-12 EP EP11746340.6A patent/EP2593461B1/en not_active Not-in-force
- 2011-07-12 BR BR112013000920A patent/BR112013000920A2/pt not_active IP Right Cessation
- 2011-07-12 WO PCT/US2011/043628 patent/WO2012009309A1/en not_active Ceased
- 2011-07-15 AR ARP110102569A patent/AR082241A1/es not_active Application Discontinuation
-
2013
- 2013-01-13 IL IL224202A patent/IL224202A/en not_active IP Right Cessation
- 2013-02-11 CO CO13027683A patent/CO6670589A2/es active IP Right Grant
- 2013-02-14 ZA ZA2013/01178A patent/ZA201301178B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120184565A1 (en) | 2012-07-19 |
| CA2805294A1 (en) | 2012-01-19 |
| CN102971325A (zh) | 2013-03-13 |
| AU2011279412A1 (en) | 2013-03-07 |
| SG186392A1 (en) | 2013-02-28 |
| JP5755739B2 (ja) | 2015-07-29 |
| MX2013000514A (es) | 2013-02-27 |
| ZA201301178B (en) | 2014-07-30 |
| AU2011279412B2 (en) | 2014-12-11 |
| KR20130041944A (ko) | 2013-04-25 |
| EA021527B1 (ru) | 2015-07-30 |
| TW201206946A (en) | 2012-02-16 |
| CO6670589A2 (es) | 2013-05-15 |
| CN102971325B (zh) | 2016-01-20 |
| WO2012009309A1 (en) | 2012-01-19 |
| JP2013531040A (ja) | 2013-08-01 |
| US8637523B2 (en) | 2014-01-28 |
| EA201270824A1 (ru) | 2013-04-30 |
| BR112013000920A2 (pt) | 2016-05-17 |
| EP2593461B1 (en) | 2016-08-17 |
| NZ606950A (en) | 2014-08-29 |
| IL224202A (en) | 2016-04-21 |
| EP2593461A1 (en) | 2013-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR082241A1 (es) | COMPUESTOS PARA REDUCIR LA PRODUCCION DE AMILOIDE b | |
| MX2020011501A (es) | Compuestos novedosos. | |
| MX2020000261A (es) | Nuevos compuestos. | |
| EA201490445A1 (ru) | Циклопропанаминовое соединение | |
| ES2655391T3 (es) | Inhibidores isoindolinona de fosfatidilinositol 3-quinasa | |
| PE20121695A1 (es) | 5-alquinil-pirimidinas | |
| CL2014003181A1 (es) | Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas. | |
| CR20180022A (es) | Derivados etinilo. | |
| EA201001595A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
| EA201391537A1 (ru) | ЭТИНИЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ mGluR5 | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| EA201370184A1 (ru) | Гетероарильные производные | |
| PH12018502457B1 (en) | Treatment for parkinson's disease | |
| PE20140165A1 (es) | Combinaciones que contienen n-(2-arilamino)arilsulfonamida | |
| EA201691046A1 (ru) | Производные этинилимидазолин-2,4-диона в качестве модуляторов метаботропного глутаматного рецептора 4 (mglur4) | |
| EA201790626A1 (ru) | Макроциклические ингибиторы lrrk2-киназы | |
| UA107002C2 (uk) | Етинільні похідні | |
| PH12016500838A1 (en) | Isoxazolines as therapeutic agents | |
| ZA202107777B (en) | Voruciclib polymorphs and methods of making and using thereof | |
| MY161403A (en) | 5- (phenyl/pyridinyl-ethinyl) -2-pyridine/ 2-pyrimidine-carborxamides as mglur5 modulators | |
| GEAP202415700A (en) | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof | |
| EA201071014A1 (ru) | Новые 7-замещенные производные 3-карбоксиоксадиазинохинолонов, способ их получения и применение в качестве антибактериальных средств | |
| PE20221003A1 (es) | Compuestos para tratar enfermedad respiratoria | |
| MY170255A (en) | Arylethynyl derivatives | |
| AR081382A1 (es) | Derivados de n-heterocicloalquil bipirrolidinilfenil amida sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades del sistema nervioso central. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |